ArticleInternational journal of heart failure2021
Incidence, Cause of Death, and Survival of Amyloidosis in Korea: A Retrospective Population-Based Study.
Article in International journal of heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Diagnostic Pitfall and Clinical Characteristics of Variant Versus Wild-Type Transthyretin Amyloid Cardiomyopathy in Asian Population: The Korean Nationwide Cohort Study.Journal of Korean medical science · 2024Article
- Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment.Korean circulation journal · 2023Review
- Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment.International journal of heart failure · 2023Review
- Temporal trends in incidence, prevalence, and death of aortic stenosis in Korea: a nationwide population-based study.ESC heart failure · 2022Article
- Multimodal Imaging and Biomarkers in Cardiac Amyloidosis.Diagnostics (Basel, Switzerland) · 2022Review
- Using Big Data to Understand Rare Diseases.International journal of heart failure · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: We sought to assess incidence, cause of death, and survival for amyloidosis. We acquired amyloidosis data from the National Health Insurance Service in Korea from 2006 through 2017 (n=2,233; male 53.5%). Methods: We calculated the age-standardized incidence rate, analyzed the survival rate (SR) using the Kaplan-Meier method, and analyzed the death risk using Cox proportional hazards methods. Results: The mean age was 57.0±16.7 years in males and 56.8±15.6 years in females (p=0.795). The proportion of death was 34.7%. The causes of death were endocrine, nutritional, and metabolic diseases (33.9%), malignant neoplasm (20.8%), and diseases of the circulatory system (9.68%). The overall age-standardized incidence rate was 0.47 persons per 100,000 persons in 2017. Overall, the 10-year SR for amyloidosis was 57.7%. Adjusted hazard ratios were 9.16 among 40s', 16.1 among 50s', 30.3 among 60s', 48.7 among 70s', 80.1 among people 80 years or older, and 1.21 in the medium-level socioeconomic position group. Conclusions: The age-standardized incidence rate of amyloidosis was about 0.5 persons per 100,000 persons in 2017. The 10-year SR of amyloidosis was about 58%. The most common cause of death was endocrine, nutritional, and metabolic diseases. The risk of death from amyloidosis increased with age and medium socioeconomic position.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.